Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5695MR)

This product GTTS-WQ5695MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5695MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7651MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ13988MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10042MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ4368MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ1212MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ4179MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ2046MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ15371MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW